ESR1 and breast carcinoma: We have also shown that the multicolor nanosystems are capable of mapping heterogeneous breast cancer cells simultaneously and can distinguish targeted TNBC cells from non-targeted HER-2(+) or ER/PR(+) breast cancer cells.